BR112021021856A2 - Combinação de marcador de microrna para diagnosticar câncer gástrico e kit de diagnóstico - Google Patents

Combinação de marcador de microrna para diagnosticar câncer gástrico e kit de diagnóstico

Info

Publication number
BR112021021856A2
BR112021021856A2 BR112021021856A BR112021021856A BR112021021856A2 BR 112021021856 A2 BR112021021856 A2 BR 112021021856A2 BR 112021021856 A BR112021021856 A BR 112021021856A BR 112021021856 A BR112021021856 A BR 112021021856A BR 112021021856 A2 BR112021021856 A2 BR 112021021856A2
Authority
BR
Brazil
Prior art keywords
hsa
mir
gastric cancer
diagnostic kit
marker combination
Prior art date
Application number
BR112021021856A
Other languages
English (en)
Portuguese (pt)
Inventor
Ruiyang Zou
Original Assignee
Mirxes Lab Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirxes Lab Pte Ltd filed Critical Mirxes Lab Pte Ltd
Publication of BR112021021856A2 publication Critical patent/BR112021021856A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112021021856A 2019-04-30 2020-04-14 Combinação de marcador de microrna para diagnosticar câncer gástrico e kit de diagnóstico BR112021021856A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910392316.2A CN110029169A (zh) 2019-04-30 2019-04-30 一种检测胃癌的miRNA标志物组合及试剂盒
PCT/CN2020/084687 WO2020220994A1 (zh) 2019-04-30 2020-04-14 一种检测胃癌的miRNA标志物组合及试剂盒

Publications (1)

Publication Number Publication Date
BR112021021856A2 true BR112021021856A2 (pt) 2022-01-18

Family

ID=67241908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021856A BR112021021856A2 (pt) 2019-04-30 2020-04-14 Combinação de marcador de microrna para diagnosticar câncer gástrico e kit de diagnóstico

Country Status (13)

Country Link
US (1) US20220186320A1 (https=)
EP (1) EP3967767A4 (https=)
JP (2) JP7676321B2 (https=)
KR (1) KR20220009970A (https=)
CN (4) CN117683886A (https=)
AU (1) AU2020265027A1 (https=)
BR (1) BR112021021856A2 (https=)
CL (1) CL2021002852A1 (https=)
CO (1) CO2021015520A2 (https=)
MX (1) MX2021013424A (https=)
PH (1) PH12021552764A1 (https=)
SG (1) SG11202112095VA (https=)
WO (1) WO2020220994A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117683886A (zh) * 2019-04-30 2024-03-12 觅瑞实验室私人有限公司 一种检测胃癌的miRNA标志物组合及试剂盒
CN111321224B (zh) * 2019-12-27 2023-09-15 陈锦飞 一种用于诊断或辅助诊断胃癌的miRNA生物标志物组合及其试剂盒
CN111471764B (zh) * 2019-12-27 2023-09-15 陈锦飞 一种用于筛查或辅助诊断胃癌的生物标志物组合及其试剂盒和应用
CN111312405A (zh) * 2020-02-12 2020-06-19 宁德市闽东医院 一种健康体检胃癌筛查评估及管理系统
CN111471683B (zh) * 2020-04-15 2021-09-07 湖南省科域生物医药科技有限公司 miR-93-5p作为诊断和治疗胃癌标志物的应用
CN112226514B (zh) * 2020-11-23 2021-08-03 苏州京脉生物科技有限公司 用于早期胃癌检测的标志物组合、试剂盒及其应用
CN113151413A (zh) * 2021-04-28 2021-07-23 杭州觅因生物科技有限公司 一种具有校准功能的microRNA检测试剂盒
CN113186285B (zh) * 2021-05-10 2022-05-24 深圳市展行生物有限公司 一种辅助诊断胃癌的方法及其使用的miRNA组合
CN114875151B (zh) * 2022-06-15 2023-05-16 北京肿瘤医院(北京大学肿瘤医院) 血浆外泌体生物标志物在胃癌新辅助化疗敏感人群筛查或疗效预测中的应用
CN116179691A (zh) * 2022-09-07 2023-05-30 苏州大学附属第一医院 一种胃癌组合标志物及标志物模型的建立方法
CN116926192B (zh) * 2023-05-17 2025-01-24 山东大学 一种基于链置换反应的肿瘤标志物miRNA与mRNA荧光共检测方法及其在胃癌诊断中的应用
CN119351558A (zh) * 2024-12-10 2025-01-24 西藏自治区人民政府驻成都办事处医院 一种检测胃癌的标志物、检测试剂盒及药物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716906A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer
CN102892897B (zh) * 2009-12-24 2016-08-03 复旦大学 用于肺癌的微rna表达谱分析的组合物和方法
US9850527B2 (en) 2010-06-14 2017-12-26 National University Of Singapore Modified stem-loop oligonucleotide mediated reverse transcription and base-spacing constrained quantitative PCR
KR101381894B1 (ko) * 2012-02-28 2014-04-14 부산대학교 산학협력단 위암의 림프절 전이 진단 마커로서의 혈청 miRNA
CN103937888B (zh) * 2014-04-14 2016-08-17 上海交通大学 鉴别胃癌的血浆microRNA标志物的筛选与应用
EP4718079A2 (en) * 2014-06-16 2026-04-01 Toray Industries, Inc. Stomach cancer biomarker and detection method
EP3177739B1 (en) * 2014-08-07 2019-10-23 Agency For Science, Technology And Research Microrna biomarker for the diagnosis of gastric cancer
WO2016034715A2 (fr) * 2014-09-05 2016-03-10 Prestizia Methode de prediction de l'evolution clinique du cancer colorectal
WO2016144265A1 (en) * 2015-03-09 2016-09-15 Agency For Science, Technology And Research Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
CN105219867B (zh) * 2015-11-02 2016-08-17 北京博奥医学检验所有限公司 用于胃癌诊断的miRNA生物标志物及检测试剂盒
CN106086178B (zh) * 2016-06-16 2020-03-31 朱伟 一种与胃癌辅助诊断相关的血清miRNA标志物及其应用
CN106755377B (zh) * 2016-12-12 2021-05-25 浙江省中医院 一种胃癌血清学检测鉴定试剂盒及方法
CN107746880B (zh) * 2017-11-01 2018-12-14 健生生物技术有限公司 一种基于RT-qPCR法检测胃癌的试剂盒及其制备方法和应用
CN109609630B (zh) * 2018-12-03 2023-01-13 哈尔滨医科大学 用于早期胃癌诊断的分子标志物及其应用
CN117683886A (zh) * 2019-04-30 2024-03-12 觅瑞实验室私人有限公司 一种检测胃癌的miRNA标志物组合及试剂盒

Also Published As

Publication number Publication date
JP2025114665A (ja) 2025-08-05
WO2020220994A1 (zh) 2020-11-05
CL2021002852A1 (es) 2022-06-10
CN117683886A (zh) 2024-03-12
EP3967767A4 (en) 2023-06-14
JP7676321B2 (ja) 2025-05-14
MX2021013424A (es) 2022-02-11
CN117683885A (zh) 2024-03-12
EP3967767A1 (en) 2022-03-16
AU2020265027A1 (en) 2021-12-09
CN115537466A (zh) 2022-12-30
CN110029169A (zh) 2019-07-19
KR20220009970A (ko) 2022-01-25
PH12021552764A1 (en) 2022-07-11
US20220186320A1 (en) 2022-06-16
CO2021015520A2 (es) 2022-01-17
JP2022533033A (ja) 2022-07-21
SG11202112095VA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
BR112021021856A2 (pt) Combinação de marcador de microrna para diagnosticar câncer gástrico e kit de diagnóstico
ES2973279T3 (es) Usos de medicamento de duloxetina·HCl en la preparación de una composición farmacéutica para el tratamiento de cáncer
BR112022005026A2 (pt) Conjugados terapêuticos
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
EP3064584A3 (en) Micro rna-based methods and compositions for the diagnosis, prognosis and treatmentof gastric cancer
MX2011008429A (es) Metodos y composiciones para diagnostico y tratamiento del cancer.
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BR112013017140A8 (pt) Polímeros reticulados e implantes provenientes de polioxazolina eletrofilicamente ativada
MX2011009808A (es) Agentes de elaboracion de imagen optica.
BRPI0917920B8 (pt) expansão direcional de dispositivos intraluminais
BR112012018954A2 (pt) derivados de hetaril-[1,8]naftiridina
EA200901550A1 (ru) Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
BR112013025517A2 (pt) uso de 2,3-diidroimidazo[1,2-c]quinazolinas substituídas
BR112019024717A2 (pt) nanopartículas ultrapequenas marcadas com zircônio-89 e métodos das mesmas
EP4623991A3 (en) Methods for the storage of whole blood, and compositions thereof
EA202091533A1 (ru) Способы лечения диабета, гепатита и/или воспалительного заболевания печени
NO20076119L (no) Diagnostisk markor for diabetiske vaskulaere komplikasjoner
BRPI0315735B8 (pt) método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico
BR112018005494A2 (pt) composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença.
Alempijevic et al. Change in the incidence and anatomic distribution of colorectal adenoma and cancer over a period of 20 years–A single center experience
KR101640165B1 (ko) 3-하이드록시-3'',4''-디메톡시플라본을 포함하는 뇌종양 전이 억제용 조성물
WO2014190311A3 (en) Defective mismatch repair and benefit from bevacizumab for colon cancer
Jha et al. Focal intestinal lymphangiectasia: an unusual cause of acute overt obscure gastrointestinal bleeding